Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.

Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong SH, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J, Choueiri TK

Open source

DOI: 10.3389/fonc.2023.1223282
Published: 2023
Container: Frontiers in oncology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2023.1223282,
  title = {Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.},
  author = {Grünwald V and Powles T and Eto M and Kopyltsov E and Rha SY and Porta C and Motzer R and Hutson TE and Méndez-Vidal MJ and Hong SH and Winquist E and Goh JC and Maroto P and Buchler T and Takagi T and Burgents JE and Perini R and He C and Okpara CE and McKenzie J and Choueiri TK},
  year = {2023},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2023.1223282},
  url = {https://doi.org/10.3389/fonc.2023.1223282}
}

RIS

TY  - JOUR
TI  - Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
AU  - Grünwald V
AU  - Powles T
AU  - Eto M
AU  - Kopyltsov E
AU  - Rha SY
AU  - Porta C
AU  - Motzer R
AU  - Hutson TE
AU  - Méndez-Vidal MJ
AU  - Hong SH
AU  - Winquist E
AU  - Goh JC
AU  - Maroto P
AU  - Buchler T
AU  - Takagi T
AU  - Burgents JE
AU  - Perini R
AU  - He C
AU  - Okpara CE
AU  - McKenzie J
AU  - Choueiri TK
PY  - 2023
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2023.1223282
UR  - https://doi.org/10.3389/fonc.2023.1223282
ER  -

APA

V, G., T, P., M, E., E, K., SY, R., C, P., R, M., TE, H., MJ, M., SH, H., E, W., JC, G., P, M., T, B., T, T., JE, B., R, P., C, H., CE, O., J, M., & TK, C. (2023). Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.. Frontiers in oncology. https://doi.org/10.3389/fonc.2023.1223282

Source records

pubmed · retrieved 2026-09-25T08:11:20.565Z
europe-pmc · retrieved 2026-09-25T08:11:20.581Z
doaj · retrieved 2026-09-25T08:11:20.581Z